Program Visegrad meeting

12. března 2025, sál Rubín, Clarion Congress Hotel Ostrava

16.30-17.00

Welcome reception, Hájek R. (Ostrava)

PART I: MULTIPLE MYELOMA

17.00-17.15

Intrabone 'Boost' of CD34+ Cells for Patients with Poor Graft Function After AlloHSCT, Czerw T. (Gliwice)

17.15-17.25

Tandem autoHSCT with HD-Mel and Total Marrow Irradiation for MM (200 Patients Treated in Gliwice), Marciniak D. (Gliwice)

17.25-17.35

Overview of Research Activities in Ostrava: Circulating Tumor Cells & Measurable Residual Disease in Multiple Myeloma, Žihala D., Muroňová L. (Ostrava)

17.35-17.45

Overview of Research Activities in Ostrava: Spectral Flow Cytometry & Genomics in Multiple Myeloma, Venglář O., Ševčíková T. (Ostrava)

17.45-18.00

From ATLAS to TITAN: Projects of the Polish Myeloma Consortium in Maintenance Therapy Research, Dytfeld D. (Poznań)

18.00-18.10

Bone Marrow Adipocytes in the Multiple Myeloma Niche, Kellermayer Z. (Pécs)

18.10-18.30 

Coffee break

PART II: CELL THERAPIES & IMMUNOMONITORING

18.30-18.40

Development of Non-Viral 'Off-the-Shelf' CAR-T Cell Product Targeting Multiple Myeloma: 'Made in Ostrava', Alzubi J., Celichowski P. (Ostrava)

18.40-18.55

Allogeneic iNKT Cells Are on The Way, Holubová M. (Plzeň)

18.55-19.10

Current Status of CAR-T Cell Production at ÚHKT (CAR123 for AML, CAR19 for R/R ALL and B-NHL), Vydra J., Otáhal P. (Praha)

19.10-19.20

Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment, Anilkumar Sithara A. (Ostrava)

19.20-19.30

Depletion of Mature B Cells and Normal Plasma Cells after Bispecific Antibody Treatments in R/R Multiple Myeloma & Immunomonitoring Project, Žihala D., Mihályová J. (Ostrava)

PART III: DISCUSSION

19.30 +

Discussion I: Potential cooperative projects

Discussion II: The Issue & Challenges of Intellectual Property in Modern and Gene Therapy Products – introduced by Petr Lesný (Praha)